HEMORRHAGIC SHOCK TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Hemorrhagic Shock Treatment Market– Drivers

Increasing research and development activities in hemorrhagic shock treatment

Increasing research and development in the field of hemorrhagic shock treatment is expected to drive the global hemorrhagic shock treatment market growth over the forecast period. For instance, on March 25, 2023, John Wiley & Sons, Inc, U.S. based multinational publishing company published an article explaining several patient anti-shock therapies mitigate the damage caused by ischemia and reperfusion, enabling the subjects to better tolerate acute blood loss and hemorrhagic shock. Ethinyl estradiol sulfate, an estrogen derivative, reduces damage caused by apoptosis, nitric oxide (NO) production, and inflammation by improving cardiovascular performance in rodent and pig models, improving O2 delivery, and contributing to the restoration of the pre-shock state.

Global Hemorrhagic Shock Treatment Market: Restraints

Risk related to hemorrhagic shock treatment

The risk of developing adverse reactions on several factors related to treatment can hamper the growth of the global hemorrhagic shock treatment market. For instance, on July 27, 2020, Daiichi Sankyo Company, Limited, a company focused on pharmaceutical therapies explained the safety of ENHERTU was evaluated in a pooled analysis of patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast01 and study DS8201-A-J101. ENHERTU was administered by intravenous infusion once every three weeks. The median duration of treatment was 7 months. Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were interstitial lung disease, pneumonia, vomiting, nausea, cellulitis, hypokalemia, and intestinal obstruction. Fatalities due to adverse reactions occurred in 4.3% of patients including interstitial lung disease, and the following events occurred in one patient each: acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemorrhagic shock.

To counterbalance this restrain, more effective treatments should be introduced to reduce the adverse reactions of drugs.